Max Healthcare reports strong growth in Q3…

Max Healthcare reports strong growth in Q3,

New Delhi/Mumbai: Max Healthcare Institute Ltd (MHIL, ‘The Company’), one of the largest private sector healthcare services company in India, announced results for the three months ended December 31, 2020.

Home Improvement

The gross revenues rose to INR 1160 Cr during the third quarter reflecting a growth of 6% YoY and 24% QoQ.

The network EBITDA rose to INR 253 Cr versus INR 160 Cr in Q3 last year and INR 143 Cr in the previous quarter
(Q2 FY 21). This is the highest ever quarterly EBITDA achieved by the company.

The company also announced a significant improvement in EBITDA margins, which stood at 23.2% for the quarter,
up from 15.8% in the corresponding quarter in FY 20. The EBITDA margin for the previous quarter was 16.2%.

The PAT grew to INR 135 Cr from INR 36 Cr, an increase of 276% QoQ.

The Net debt (including put option liabilities) reduced by INR 121 Cr during the quarter and stood at INR 1867 Cr on
Dec 31st 2020 as against INR 1988 Cr on Sept 30th , 2020.

This financial performance was driven by an increase in footfalls of OPD patients, IPD occupancy and improved
ARPOB. The network saw occupancy relating to COVID-19 decline in the latter half of the quarter and an increase in
the surgical cases in key specialities. The significant improvement in EBITDA was also underpinned by long term
structural cost savings program initiated in the previous financial year and followed up with additional initiatives in
the current financial year.

The revenue from international medical tourists witnessed an uptick during the quarter and grew by 2.3 times of
Q2 FY 21, reaching ~40% of pre-Covid levels. In order to increase focus on international medical tourism business,
the Board has approved to establish a subsidiary in UAE, which will focus on reaching out to a greater number of
patients and capturing a higher market share from Africa, West Asia and Eastern Europe.

The company continued to invest in technology and clinical talent. Max Vaishali is in advanced stage to commission
its TomoTherapy® System which will offer a revolutionary radiotherapy for cancer treatment. With a view to
enhance top-notch clinical talent, network hospitals hired more than 20 senior consultants during the quarter.
Announcing the Q3 results, Abhay Soi, Chairman and MD, Max Healthcare Institute Ltd, commented, “We are
pleased with our Q3 results, which reflect continued best in class operating performance underpinned by strong
fundamentals. These results also demonstrate the resilience of our clinical and non-clinical teams to serve the
communities during challenging times. We are committed to highest standard of clinical excellence and patient
care supported by latest technology”.

Financial and Operational Highlights:

Clinical Update:

• Treated over 20,000 COVID-19 patients at hospitals and ~2,000 patients at home/extended care facilities till
December 2020
• ~2.80L RT-PCR tests done as of December 31st,2020
• Successfully treated India’s first case of Lung Decortication of a COVID-19 recovered patient
• India’s first Esophagus Y tracheal stent and a “stent on stent” – double stenting / double Y stenting done in a 77
yea- old male k/c/o squamous cell carcinoma
• Successfully diagnosed and treated a rare case of Steroid Responsive Encephalopathy Associated With
Autoimmune Thyroiditis (SREAT): Hashimoto’s encephalopathy in a 49 year old male
• Prevented exenteration (removal of eyeball) on post COVID-19 patient with orbital mucormycosis and lost
vision adopting the latest techniques
• Successfully performed cadaveric transplant involving both liver and kidney transplantation

Research and Academics:

• 85 national and international publications, with top-3 being from the oncology, nephrology and urology
• 30 studies and trials on COVID-19 indications and 45 non-COVID-19 clinical trials ongoing across MHC
• Ongoing IMT program at Max Healthcare, with a total of 25 doctors enrolled
• NABH accreditation for Ethics committee at Max Saket (East block) under clinical trial program
• 70 allied health internship, 17 observership and 3 fellowship students joined
• DNB accreditation approval in 25 specialties; 5 DNB specialties applied for renewal accreditation; total strength
of DNB residents across Max network at 429 currently

Leave a Reply

Your email address will not be published. Required fields are marked *